This prospective study was designed to assess the outcomes (survival and failure patterns)
of therapy for localized esophageal cancer with conventional dose radiation (RT; 50.4 Gy)
with concurrent continuous infusion 5-fluorouracil (5-FU) and weekly carboplatin/paclitaxel.
Patients with less than complete response (CR) or partial response (PR) received dose
escalation of radiation to 59.4 Gy with the same chemotherapy.
we prospectively enrolled patients with T1–4, N0–1, M0–1a esophageal carcinoma to receive
paclitaxel 45 mg/m2 IV over 1 hour and carboplatin AUC 2 IV over 30 minutes on days 1, 8,
15, 22, 29 and 36. 5-FU 225mg/m2 was delivered as a continuous infusion on days 1–38. RT
was given 1.8Gy 5 days/wk for 5.5 wks (50.4Gy in 28 fx). After 6–8 weeks, patients
underwent repeat staging with computed tomography (CT) scan, endoscopic ultrasound (EUS),
and biopsy. Patients with a positive biopsy, or less than PR by CT and EUS, received a
boost of 9 Gy with the same concurrent chemotherapy. Patients were followed every 4 months
with CT/EUS first year, every 6 months thereafter.
- T1–4, N0–1, M0–1a esophageal carcinoma
- distant metastases